Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Zylidac Bio and Prolific Machines partner to scale Prolific’s next-generation biologics manufacturing platform to GMP production (opens in a new tab)

news-medical.net · 2026-10-22

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

18 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1

The story

Zylidac Bio and Prolific Machines partner to scale Prolific’s next-generation biologics manufacturing platform to GMP production

news-medical.net · 2026-10-22

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

The literature search

18 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 14 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedZylidac Bio and Prolific Machines announced a partnership to scale Prolific's next-generation biologics manufacturing platform from early development through GMP production.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedProlific's technology uses light to control protein expression in engineered cell lines, with the article saying this enables substantial gains in productivity, superior on-target quality, and precise process control.View evidenceHide evidence

As statedsubstantial gains

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedThe platform combines optogenetics-enabled cell lines, illumination systems compatible with standard bioreactors, AI-driven process optimization, and advanced analytics, and is described as being useful for difficult-to-express proteins such as multi-specific antibodies, fusion proteins, cytokines, and other complex modalities.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedProlific has reported a record-breaking productivity milestone of 21 g/L in a 15-day intensified fed-batch CHO run for a monoclonal antibody at small scale, along with up to three-fold titer increases for other complex formats.View evidenceHide evidence

As stated21 g/L; 15-day; up to three-fold

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedUnder the agreement, Zylidac Bio will first complete a tech transfer of Prolific's process at 50-liter scale, then the companies plan to scale client programs to 250 liters and into GMP manufacturing scale.View evidenceHide evidence

As stated50-liter scale; 250 liters

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe partnership is presented as creating an end-to-end development and manufacturing pathway from cell line development through drug substance, drug product manufacturing, fill-finish, and packaging.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Explore all search results